Pruritus in primary biliary cholangitis is under-recorded in patient medical records

被引:3
|
作者
Gungabissoon, Usha [1 ]
Smith, Helen T. [1 ]
von Maltzahn, Robyn [1 ]
Logie, John [1 ]
Fairburn-Beech, Jolyon [1 ]
Ma, Liyuan [2 ]
Dhirishiya, P. [3 ]
McGirr, Ashleigh [4 ]
Hunnicutt, Jake N. [2 ]
Rowe, Christopher L. [5 ]
Tierney, Meghan [5 ]
Friedler, Haley S. [5 ]
机构
[1] GSK, London, England
[2] GSK, Collegeville, PA USA
[3] GSK, Bangalore, India
[4] GSK, Mississauga, ON, Canada
[5] PicnicHlth, San Francisco, CA USA
来源
BMJ OPEN GASTROENTEROLOGY | 2024年 / 11卷 / 01期
关键词
QUALITY OF LIFE; CHOLESTATIC LIVER DISEASES; CHOLESTASIS; HEPATOBILIARY DISEASE; EPIDEMIOLOGY; QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; MANAGEMENT; BEZAFIBRATE; CIRRHOSIS;
D O I
10.1136/bmjgast-2023-001287
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective Cholestatic pruritus in primary biliary cholangitis (PBC) reduces patients' health-related quality of life (HRQoL). Despite this, existing research suggests that pruritus is under-recorded in patients' health records. This study assessed the extent to which pruritus was recorded in medical records of patients with PBC as compared with patient-reported pruritus, and whether patients reporting mild itch were less likely to have pruritus recorded. We also evaluated clinico-demographic characteristics and HRQoL of patients with medical record-documented and patient-reported pruritus.Design This cross-sectional study used clinical information abstracted from medical records, together with patient-reported (PBC-40) data from patients with PBC in the USA enrolled in the PicnicHealth cohort. Medical record-documented pruritus was classified as 'recent' (at, or within 12 months prior to, enrolment) or 'ever' (at, or any point prior to, enrolment). Patient-reported pruritus (4-week recall) was assessed using the first PBC-40 questionnaire completed on/after enrolment; pruritus severity was classified by itch domain score (any severity: >= 1; clinically significant itch: >= 7). Patient clinico-demographic characteristics and PBC-40 domain scores were described in patients with medical record-documented and patient-reported pruritus; overlap between groups was evaluated. Descriptive statistics were reported.Results Pruritus of any severity was self-reported by 200/225 (88.9%) patients enrolled; however, only 88/225 (39.1%) had recent medical record-documented pruritus. Clinically significant pruritus was self-reported by 120/225 (53.3%) patients; of these, 64/120 (53.3%) had recent medical record-documented pruritus. Patients reporting clinically significant pruritus appeared to have higher mean scores across PBC-40 domains (indicating reduced HRQoL), versus patients with no/mild patient-reported pruritus or medical-record documented pruritus.Conclusion Compared with patient-reported measures, pruritus in PBC is under-recorded in medical records and is associated with lower HRQoL. Research based only on medical records underestimates the true burden of pruritus, meaning physicians may be unaware of the extent and impact of pruritus, leading to potential undertreatment.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis
    Shen, Nan
    Pan, Jielu
    Miao, Hongyu
    Zhang, Haiyan
    Xing, Lianjun
    Yu, Xiao
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (07) : 7697 - 7705
  • [42] Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response
    Reig, Anna
    Sese, Pilar
    Pares, Albert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (01): : 49 - 55
  • [43] Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
    Marlyn J. Mayo
    Elizabeth Carey
    Helen T. Smith
    Andrea R. Mospan
    Megan McLaughlin
    April Thompson
    Heather L. Morris
    Robert Sandefur
    W. Ray Kim
    Christopher Bowlus
    Cynthia Levy
    Digestive Diseases and Sciences, 2023, 68 : 995 - 1005
  • [44] BEZAFIBRATE ALLEVIATES PRURITUS AND DECREASES SPECIFIC CIRCULATING METABOLITES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
    Reig, A.
    Perez-Cormenzana, M.
    Sese, P.
    Mayo, R.
    Castro, A.
    Pares, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S429 - S429
  • [45] Nutrition Concerns of the Patient with Primary Biliary Cirrhosis or Primary Sclerosing Cholangitis
    Alnounou, Mustafa
    Munoz, Santiago J.
    PRACTICAL GASTROENTEROLOGY, 2006, 30 (04) : 92 - 103
  • [46] Asymptomatic Primary Biliary Cholangitis in a Young Patient: An Incidental Finding
    Kamarudin, Norhidayah
    Ding, Chuan Hun
    Isa, Nurismah Md
    Pauzi, Suria Hayati Md
    Wahab, Asrul Abdul
    GAZI MEDICAL JOURNAL, 2020, 31 (02): : 201 - 203
  • [47] Biliary Candidiasis Masquerading as Cholangiocarcinoma in a Patient With Primary Sclerosing Cholangitis
    Stratton, Amy N.
    Kwok, Ryan M.
    Satoskar, Rohit S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S390 - S391
  • [48] The Pneumonia That Won't Resolve in a Patient with Primary Biliary Cholangitis
    Twomey, K.
    Domaradzki, L.
    Stefanski, M. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [49] Resolution of Jaundice in a Patient With Primary Biliary Cholangitis on Obeticholic Acid
    Barnhill, Michele
    Rangnekar, Amol
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S1192 - S1192
  • [50] Fenofibrate in a patient with primary biliary cholangitis with an inadequate response to bezafibrate
    Zhou, Yangyang
    Gao, Haonan
    Song, Yuhu
    PORTAL HYPERTENSION & CIRRHOSIS, 2023, 2 (04): : 192 - 193